Avanos Medical Q1 2024 Adj EPS $0.19 Misses $0.21 Estimate, Sales $166.100M Beat $162.900M Estimate
Portfolio Pulse from Benzinga Newsdesk
Avanos Medical (NYSE:AVNS) reported Q1 2024 adjusted EPS of $0.19, missing the $0.21 estimate, and sales of $166.1M, beating the $162.9M estimate. This represents a 29.63% decrease in EPS and a 4.27% increase in sales year-over-year.

May 02, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Avanos Medical reported a Q1 2024 adjusted EPS of $0.19, missing estimates, but sales of $166.1M exceeded expectations.
The miss in EPS could negatively impact investor sentiment, but the beat on sales might offset this. The mixed results present a neutral short-term outlook for AVNS stock, as the sales growth could be seen as a positive sign of the company's revenue-generating capability, while the miss on EPS highlights potential cost or operational challenges.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100